Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Predictive factors for successful treatment-free remission in patients with chronic myeloid leukemia: A pooled analysis

Fadi Haddad, Hagop Kantarjian, Mauricette Michallet, Christophe Bouvier, Ghayas Issa, Koji Sasaki, Julien Bollard, Julie Hildt, Sara Dellasala, Vincent Alcazer, Elias Jabbour, Franck Nicolini

Blood (2025) 146 (Supplement 1): 5550.

https://doi.org/10.1182/blood-2025-5550

Published: 2025

Journal Articles

Thymoglobuline and grafalon show comparable transplant outcomes in patients with aplastic anemia undergoing allogeneic stem cell transplantation: A multicenter EBMT saawp study of 1603 patients

Blood (2025) 146 (Supplement 1): 3192.

https://doi.org/10.1182/blood-2025-3192

Published: 2025

Journal Articles

A machine learning approach identifies a transcriptomic signature predicting treatment-free remission in chronic myeloid leukemia

Vincent Alcazer, Stéphanie Dulucq, Isabelle Mosnier, Kaddour Chabane, Pauline Bertin-Mourot, Sandrine Derruau, Marie Balsat, Hélène Labussière-Wallet, Pierre Sujobert, François-Xavier Mahon, Gabriel Etienne, Franck Nicolini, Sandrine Hayette

Blood (2025) 146 (Supplement 1): 76.

https://doi.org/10.1182/blood-2025-76

Published: 2025

Journal Articles

Predicting algorithm for GRFS after allogeneic hematopoietic stem cell transplantation: A study by the SFGM-TC

Estelle Hamon, Mihaela Juganaru, Guillaume Muller, Hélène Labussière-Wallet, Vincent Alcazer, Martin Carre, Jacques-Olivier Bay, Elisabeth Daguenet, Jerome Cornillon

Blood (2025) 146 (Supplement 1): 4299.

https://doi.org/10.1182/blood-2025-4299

Published: 2025

Journal Articles

Retromomelo: Real-world use of momelotinib – the french experience from the FIM group

Mathilde Chanut, Imane Belhadi, Emmanuel Raffoux, Juliette Soret, Geoffroy Venton, Vincent Alcazer, Lenaig Le Clech, Jean-Christophe Ianotto, Mathieu Meunier, Paul Denous Chataigner, Mathilde Hunault, Ugo Thévenet, Elsa Lestang, Antoine Bonnet, Rafael Daltro De Oliveira, Ahmad Aljijakli, Florence Sabirou, Lina Benajiba, Jean-Jacques Kiladjian

Blood (2025) 146 (Supplement 1): 7316.

https://doi.org/10.1182/blood-2025-7316

Published: 2025

Journal Articles

Celfib-AI: A machine learning model to predict bone marrow fibrosis and cellularity from complete blood count – a multicenter model development and validation study in France

Blood (2025) 146 (Supplement 1): 3801.

https://doi.org/10.1182/blood-2025-3801

Published: 2025

Journal Articles

Additional genetic abnormalities (AGA) and microhomology end-joining DNA repair (MMEJ) signatures influence the outcome of newly diagnosed chronic phase (CP) CML: Ancillary study of the Trial of imatinib after ponatinib induction (TIPI)

Franck Nicolini, Francoise Huguet, Aude Charbonnier, Martine Escoffre-Barbe, Gabrielle Roth-Guepin, Shanti Amé, Emilie Cayssials, Mathieu Meunier, Charlotte Doublet, Vincent Alcazer, Stéphane Morisset, Romaine Mayet, Gwenaëlle Garin, Gabriel Etienne, Ivan Sloma, Olivier Mansier, Stéphanie Dulucq

Blood (2025) 146 (Supplement 1): 3773.

https://doi.org/10.1182/blood-2025-3773

Published: 2025

Journal Articles

A baseline transcriptomic signature predictive of clinical response to menin inhibitors in AML : The PRE-men retrosprospective Study

Vincent Alcazer, Sandrine Hayette, Pauline Bertin-Mourot, Juliette Helluin, Marie-Virginie Larcher, Hélène Labussière-Wallet, Sandrine Loron, Gaëlle Fossard, Sophie Ducastelle-Lepretre, Marie Balsat, Anne-Marie Daull, Fiorenza Barraco, Lila Gilis, Zofia Gross, Kaddour Chabane, Pierre Sujobert, Mael Heiblig

Blood (2025) 146 (Supplement 1): 3482.

https://doi.org/10.1182/blood-2025-3482

Published: 2025

Journal Articles

Thrombocytosis drives alteration of primary hemostasis and acquired von willebrand syndrome occurrence in myeloproliferative neoplasms

Gabriel Antherieu, Hamdi Rezigue, Marie-Odile Geay-Baillat, Sandrine Loron, Marie Balsat, Hélène Labussière-Wallet, Marie-Virginie Larcher, Vincent Alcazer, Sophie Ducastelle-Lepretre, Gaëlle Fossard, Zofia Gross, Fiorenza Barraco, Lila Gilis, Anne-Marie Daull, Herve Ghesquieres, Christophe Nougier, Yesim Dargaud, Mael Heiblig

Blood (2025) 146 (Supplement 1): 5570.

https://doi.org/10.1182/blood-2025-5570

Published: 2025

Journal Articles

Efficacy and Safety of Pegcetacoplan in PNH Patients with Extra-Vascular Hemolysis Under Anti-C5: The Real-Life Experience of the National French Reference Center

Flore Sicre de Fontbrune, Edouard Forcade, Louis Terriou, Alice Garnier, Vincent Alcazer, Nicolas Daguindau, Lynda Maafa, Isabelle Brindel, Regis Peffault de Latour, Sylvie Chevret

Blood (2024) 144 (Supplement 1): 1321.

https://doi.org/10.1182/blood-2024-199472

Published: 2024

Journal Articles

Identification of Individual Risk Factors for Treatment Free Remission (TFR) Failure in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients: Predictive Models Developed on a Nationwide Clinical and Claim Database

Jules Chassetuillier, Meriem Benmerad, Pierre-Louis Lecoq, Romain Favier, Matthieu Trancart, Sandrine Hayette, Vincent Alcazer, Christophe Bouvier, Julien Bollard, Audrey Lajoinie, Franck E. Nicolini

Blood (2023) 142 (Supplement 1): 6369.

https://doi.org/10.1182/blood-2023-179970

Published: 2023

Journal Articles

Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study

Franck E. Nicolini, Elisabetta Abruzzese, Gabrielle Roth-Guepin, Rami Abi-Tayeh, Vincent Alcazer, Sandrine Hayette, Stéphane Morisset, Françoise Huguet, Miriam Iezza, Fausto Castagnetti, Delphine Rea

Blood (2023) 142 (Supplement 1): 1799.

https://doi.org/10.1182/blood-2023-178326

Published: 2023

Journal Articles

Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line, in Real-Life Conditions: Influence of Switching to Another TKI Prior to Cessation.

Franck E. Nicolini, Vincent Alcazer, Pascale Cony-Makhoul, Stéphanie Dulucq, Sandrine Hayette, Stéphane Morisset, Rachel Parat, Christophe Bouvier, Gabriel Etienne

Blood (2022) 140 (Supplement 1): 3918–3919.

https://doi.org/10.1182/blood-2022-163376

Published: 2022

Journal Articles

The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different

Franck E. Nicolini, Vincent Alcazer, Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Stephane Morisset, Christophe Bouvier, Francois-Xavier Mahon, Gabriel Etienne, Delphine Rea

Blood (2021) 138 (Supplement 1): 2552.

https://doi.org/10.1182/blood-2021-146722

Published: 2021

Journal Articles

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Franck E Nicolini, MDPhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD, Stephanie Dulucq, PharmD, PhD, Sandrine Hayette, PhD, Stephane Morisset, BioStat, Jean-Michel Cayuela, PharmD, PhD, Marie-Pierre Fort, PhD, Christophe Bouvier, CRA, Clemence Deteix-Santana, MD, Etienne Lengline, MD, Delphine Rea, MDPhD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139921

Published: 2020

Journal Articles

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Franck Emmanuel Nicolini, MD PhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD PhD, Stephanie Dulucq, PhD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Villa, MD, Mohamad Sobh, PharmD, Stephane Morisset, Stat, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2018) 132 (Supplement 1): 3014.

https://doi.org/10.1182/blood-2018-99-113044

Published: 2018

Journal Articles

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Blood (2018) 132 (Supplement 1): 48.

https://doi.org/10.1182/blood-2018-99-113058

Published: 2018

Journal Articles

Impact of Body Mass Index on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib in First-Line

Gaelle Fossard, MD, Vincent Alcazer, MD, Marie Balsat, MD, Helene Labussiere-Wallet, MD, Stephane Morisset, Stat, Mohamad Sobh, Isabelle Tigaud, MD, Pierre Sujobert, MD PhD, Mauricette Michallet, MD PhD, Franck Emmanuel Nicolini, MD PhD

Blood (2017) 130 (Supplement 1): 2900.

https://doi.org/10.1182/blood.V130.Suppl_1.2900.2900

Published: 2017

Journal Articles

Response to Ponatinib Is Not Related to the Drug Plasma Levels in Chronic Phase CML

Franck Emmanuel Nicolini, MD PhD, Delphine Rea, MD, Vincent Alcazer, MD, Francoise Huguet, MD, Laurence Legros, MD PhD, Gaelle Fossard, MD, Elodie Grockowiak, PhD, Stephane Morisset, Stat, Pierre Sujobert, MD PhD, Mohamad Sobh, Mauricette Michallet, MD PhD, Francois Parant, PharmD, Marie-Claude Gagnieu, PharmD

Blood (2017) 130 (Supplement 1): 2901.

https://doi.org/10.1182/blood.V130.Suppl_1.2901.2901

Published: 2017

Journal Articles

Characterisation of Molecular Relapse Profiles after Tyrosine Kinase Inhibitor Cessation in Patients Eligible for Treatment-Free Remission Strategies in Chronic Phase CML

Franck E Nicolini, MD PhD, Vincent Alcazer, MD, Stephanie Dulucq, PharmD, PhD, Marie Balsat, MD, Helene Labussiere, MD, Helene Lequeu, MD, Mohamad Sobh, PharmD, Stephane Morisset, Stat, Pierre Sujobert, MD PhD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2016) 128 (22): 1893.

https://doi.org/10.1182/blood.V128.22.1893.1893

Published: 2016

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Predictive factors for successful treatment-free remission in patients with chronic myeloid leukemia: A pooled analysis

Thymoglobuline and grafalon show comparable transplant outcomes in patients with aplastic anemia undergoing allogeneic stem cell transplantation: A multicenter EBMT saawp study of 1603 patients

A machine learning approach identifies a transcriptomic signature predicting treatment-free remission in chronic myeloid leukemia

Predicting algorithm for GRFS after allogeneic hematopoietic stem cell transplantation: A study by the SFGM-TC

Retromomelo: Real-world use of momelotinib – the french experience from the FIM group

Celfib-AI: A machine learning model to predict bone marrow fibrosis and cellularity from complete blood count – a multicenter model development and validation study in France

Additional genetic abnormalities (AGA) and microhomology end-joining DNA repair (MMEJ) signatures influence the outcome of newly diagnosed chronic phase (CP) CML: Ancillary study of the Trial of imatinib after ponatinib induction (TIPI)

A baseline transcriptomic signature predictive of clinical response to menin inhibitors in AML : The PRE-men retrosprospective Study

Thrombocytosis drives alteration of primary hemostasis and acquired von willebrand syndrome occurrence in myeloproliferative neoplasms

Efficacy and Safety of Pegcetacoplan in PNH Patients with Extra-Vascular Hemolysis Under Anti-C5: The Real-Life Experience of the National French Reference Center

Identification of Individual Risk Factors for Treatment Free Remission (TFR) Failure in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients: Predictive Models Developed on a Nationwide Clinical and Claim Database

Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study

Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line, in Real-Life Conditions: Influence of Switching to Another TKI Prior to Cessation.

The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Impact of Body Mass Index on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib in First-Line

Response to Ponatinib Is Not Related to the Drug Plasma Levels in Chronic Phase CML

Characterisation of Molecular Relapse Profiles after Tyrosine Kinase Inhibitor Cessation in Patients Eligible for Treatment-Free Remission Strategies in Chronic Phase CML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only